All publications

Export 162 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Price H., Dunn DT, Asboe D, Pozniak A, Gazzard B, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2009.  Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data. 18th International HIV Drug Resistance Workshop, June 2009.
Mackie N, Garvey L, Geretti AM, Harrison LJ, Tilston P, Phillips AN, Sabin CA, Dunn DT.  2011.  Predicting NNRTI resistance - do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Predictors of death and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Geretti AM, Phillips AN, Kaye S, Booth C, Garcia A, Mackie N, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels. 17th International HIV Drug Resistance Workshop, 10-14 June 2008.
Barber TJ, Harrison LJ, Asboe D, Williams I, Bansi L, Pillay D, Dunn DT.  2011.  Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.
Boyd K, Walker S, Dunn DT, Judd A, Pillay D, Menson E, Tudor-Williams G, Gibb DM.  2010.  The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK. 17th Conference on Retroviruses and Opportunistic Infections, February 2010.
Donegan K.L, Walker A.S, Dunn DT, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM.  2012.  The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.
Dunn DT, Green H, Matthias R, Woodburn P, Gifford RJM, Chrystie I, Zuckerman M., Geretti AM, Loveday C, Clark J et al..  2004.  Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.
Hue S, Villanueva RMucio, Tostevin A, Delpech V, Pozniak A, Ashton L, Pillay D, Goldstein R, UK HIV Drug Resistance Database.  2016.  Probabalistic Estimation of HIV-1 Subtype B Transmission Rates from Viral Phylogenies. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.
K Bouzidi E, White E, Mbisa JL, Phillips AN, Mackie N, Pozniak A, Dunn DT.  2014.  Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.
R
Dolling D, Nelson M, Schwenk A, Churchill D, Pillay D, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2013.  Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Hughes GJ, Leigh Brown A, Rambaut A, Lycett S, Lewis S, Fearnhill E, UK HIV Drug Resistance Database.  2008.  Recent phylodynamics of the HIV epidemic among MSM in the UK. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Tostevin A, White E, Dunn DT, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A, Churchill D, Geretti AM et al..  2016.  Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med.
Tostevin A, Stirrup OT, Mackie N, Asboe D, Pozniak A, Churchill D, Leigh Brown A, Sabin C, Smit E, Collins S et al..  2018.  Results of HIV-1 drug resistance tests performed in ART-experienced patients in the UK: patterns 2008 to 2015. BHIVA Spring.
Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P.  2018.  Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.. AIDS Res Ther. 15(1):11.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. 13th International Drug Resistance Workshop, 8-12 June 2004.
S
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn DT, Phillips AN.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
Koning FA, Castro H, Dunn DT, Mbisa JL, Cane P A, UK HIV Drug Resistance Database.  2012.  Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. BHIVA Spring.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. 24th International HIV Dynamics and Evolution.